Organovo Holdings Inc Stock Nyse
Equities
US68620A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 75K 103K | Sales 2025 * | 444K 607K | Capitalization | 10.61M 14.51M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 141 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 23.9 x |
P/E ratio 2024 * |
-0.54
x | P/E ratio 2025 * |
-0.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.09% |
Managers | Title | Age | Since |
---|---|---|---|
Keith Murphy
CEO | Chief Executive Officer | 52 | 06-12-31 |
Thomas Hess
DFI | Director of Finance/CFO | 60 | 21-09-30 |
Steve Kunszabo
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Adam Stern
BRD | Director/Board Member | 60 | 12-01-31 |
Keith Murphy
CEO | Chief Executive Officer | 52 | 06-12-31 |
David Gobel
BRD | Director/Board Member | 71 | 20-09-14 |
1st Jan change | Capi. | |
---|---|---|
+26.34% | 42.68B | |
-3.87% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.63% | 24.94B | |
-21.44% | 18.96B | |
+27.60% | 12.3B | |
-2.96% | 11.95B | |
-1.78% | 11.55B |